Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

PHOENIX, Ariz. (KVOA)— Attorney general Kris Mayes is suing a pharmaceutical company for allegedly endangering asthma ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...

GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share ...